Annovis Bio
Annovis Bio reported revenue of $0 million in fiscal 2025. The diluted share count rose 68.0%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Annovis Bio does
Annovis Bio is a drug developer working on treatments for diseases in which brain cells break down over time, such as Alzheimer's disease and Parkinson's disease. It has no products for sale. Its main drug candidate, buntanetap, is a pill designed to lower the levels of several toxic proteins that the company says damage nerve cells and their ability to communicate.
In February 2025 the company began a late-stage (Phase 3) trial of buntanetap in 760 patients with early Alzheimer's disease, with six months of treatment followed by twelve more. In January 2026 it began a longer-term study in Parkinson's patients to test the drug's safety over time, and it plans a third study in Parkinson's patients with dementia once it has more funding. It has finished 12 clinical studies so far, most of them safety studies in healthy volunteers. It relies on outside manufacturers to make the drug and on outside firms to run its trials.
Annovis has never earned revenue from selling a product. It had a net loss of $28.9 million in 2025 and ended the year with $19.5 million in cash and cash equivalents; management says there is substantial doubt it can keep operating for the next twelve months without more financing. As of February 28, 2026, it had eight full-time employees, and its offices are in Malvern, Pennsylvania.
Its biggest risks, as it describes them
- It may not be able to keep operating unless it raises more money, and raising it could dilute existing shareholders.
- Its heavy dependence on buntanetap, a single drug candidate that may never win approval or sell well.
- Alzheimer's and Parkinson's drugs have had little success, and buntanetap uses a new approach.
- Clinical trials are costly and uncertain, and good early results may not hold up in later trials.
- Its reliance on contract manufacturers to make buntanetap and on outside firms to run its trials.
Income statement
Annovis Bio lost money in fiscal 2025: a net loss of $29 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 46 | 28 | 6 | 11 | 20 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 30.5x | 4.7x | 2.4x | — | — |
| Quick ratio | 30.5x | 4.7x | 2.4x | — | — |
Cash flow
Free cash flow is cash from operations minus capital expenditure. The SEC's structured data for Annovis Bio's filings doesn't give both for any year, so free cash flow is left out.
Projections
Project Annovis Bio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $2.1 million of Annovis Bio shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 20, 2026 | Michael B HoffmanDirector | Bought | 76,344 | $1.87 | $142,784 | Form 4 |
| Apr 2, 2026 | Michael B HoffmanDirector | Bought | 713,800 | $2.10 | $1.5 million | Form 4 |
| Dec 8, 2025 | Michael B HoffmanDirector | Bought | 45,000 | $4.31 | $193,800 | Form 4 |
| Nov 24, 2025 | Michael B HoffmanDirector | Bought | 39,200 | $4.08 | $159,886 | Form 4 |
| Nov 21, 2025 | Michael B HoffmanDirector | Bought | 20,000 | $3.50 | $69,900 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | −61.50 | — | — |
| Accruals ratio | −70.2% | −22.3% | −18.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | — | — |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put Annovis Bio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Annovis Bio | FY25 | — | — | — | — | — | — | |
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue growth | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 1 | 3 | 8 | 16 | 39 | 20 | 25 |
| Operating income | −2 | −7 | −14 | −26 | −45 | −27 | −30 |
| Net income | −1 | −6 | −14 | −25 | −56 | −25 | −29 |
| Diluted EPS (US$) | −3.51 | −0.87 | −1.90 | −3.10 | −6.23 | −2.31 | −1.40 |
| Diluted shares (millions) | 0 | 6 | 8 | 8 | 9 | 12 | 21 |
| Cash flow | |||||||
| Cash from operations | −0 | −4 | −9 | −17 | −40 | −22 | −26 |
| Capital expenditure | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 2 | 5 | 9 | 5 | 4 | 2 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 0 | 8 | 46 | 28 | 6 | 11 | 20 |
| Debt incl. finance leases | 0 | — | — | — | — | — | — |
| Total assets | 1 | 8 | 46 | 36 | 10 | 14 | 21 |
| Total liabilities | 3 | 1 | 2 | 8 | 18 | 5 | 4 |
| Shareholders' equity | −9 | 8 | 44 | 28 | −8 | 9 | 17 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — |
| Free cash flow margin | — | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | — | −55.7% | −69.6% | −546.4% | −3,159.1% | −220.6% |
| Return on assets | — | −118.3% | −53.5% | −61.8% | −243.2% | −203.8% | −164.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — |